Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 7, 2010, Pages 931-934

  Pinto, Jorge L F ^a,b   Fonseca, Fernando L A ^a   Marsicano, Sarah R ^a   Delgado, Pamela O ^a   Sant'Anna, Aleksandra V L ^a   Coelho, Patrícia G ^a   Maeda, Patríca ^a   Del Giglio, Auro ^a,b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

amifostine; breast cancer; chemotherapy; microsatellite instability

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; DNA; MELPHALAN; PROTEIN MSH2;

ADULT; ARTICLE; BREAST CANCER; CELL FRACTIONATION; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL;

EID: 77954149407     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.07.0015     Document Type: Article

References (24)

1. Kouraklis G, Misiakos EP. Hereditary nonpolyposis colorectal cancer (Lynch syndrome): criteria for identification and management. Dig Dis Sci 2005 50 : 336 344.
2. Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev 2008 129 : 391 407.
3. Casorelli I et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003 2 : 547 559.
4. Ben-Yehuda D et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996 88 : 4296 4303.
5. Worrillow LJ et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003 9 : 3012 3020.
6. Fonseca FL et al. Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. Breast Cancer Res 2005 7 : R28 R32.
7. Marcu LG. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. Eur J Cancer Care (Engl) 2009 18 : 116 123.
8. Buschini A et al. Amifostine (WR-2721) selective protection against melphalan genotoxicity. Leukemia 2000 14 : 1642 1651.
9. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta 2007 1775 : 181 232.
10. Shao ZM, Nguyen M. Tumor-specific DNA in plasma of breast cancer patients. Anticancer Drugs 2002 13 : 353 357.
11. Melkonyan HS et al. Transrenal nucleic acids: from proof of principle to clinical tests. Ann N Y Acad Sci 2008 1137 : 73 81.
12. Orditura M et al. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review). Oncol Rep 1999 6 : 1357 1362.
13. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999 26 : 3 21.
14. Stemmer C et al. Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics. Clin Chem 2003 49 : 1953 1955.
15. Dietmaier W et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997 57 : 4749 4756.
16. Mougenot P et al. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer. Anticancer Res 2006 26 : 2197 2203.
17. Demokan S et al. Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer. Ann Oncol 2006 17 : 995 999.
18. Su YH et al. Detection of a K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark 2005 1 : 177 182.
19. Szarvas T et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol Rep 2007 18 : 405 409.
20. Wozniak K et al. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol 2007 81 : 519 527.
21. Adem C et al. Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer 2003 107 : 580 582.
22. Caldés T et al. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer. Teratog Carcinog Mutagen 2000 20 : 283 291.
23. Watanabe Y et al. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 2001 85 : 1064 1069.
24. Wild PJ et al. Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation. Clin Cancer Res 2004 10 : 556 564.